Adam Maeder
Stock Analyst at Piper Sandler
(3.15)
# 1,083
Out of 5,174 analysts
102
Total ratings
42.67%
Success rate
2.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Maeder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXST RxSight | Maintains: Neutral | $11 → $10 | $6.26 | +59.74% | 4 | Feb 26, 2026 | |
| TCMD Tactile Systems Technology | Maintains: Overweight | $35 → $42 | $26.86 | +56.37% | 6 | Feb 18, 2026 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $165 → $85 | $52.07 | +63.24% | 18 | Feb 12, 2026 | |
| EW Edwards Lifesciences | Reiterates: Overweight | $98 → $100 | $81.69 | +22.41% | 19 | Feb 11, 2026 | |
| RMD ResMed | Maintains: Neutral | $270 → $275 | $228.19 | +20.51% | 5 | Jan 30, 2026 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $610 → $620 | $471.91 | +31.38% | 22 | Jan 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Overweight | $150 → $135 | $104.06 | +29.73% | 4 | Jan 23, 2026 | |
| SGHT Sight Sciences | Upgrades: Overweight | $5 → $9 | $3.85 | +133.77% | 3 | Jan 5, 2026 | |
| NYXH Nyxoah | Reiterates: Overweight | $12 → $9 | $3.19 | +182.57% | 9 | Nov 14, 2025 | |
| NSPR InspireMD | Maintains: Overweight | $4.5 → $4 | $1.79 | +123.46% | 4 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $21 | $18.38 | +14.25% | 2 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 → $8 | $1.46 | +449.83% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.80 | +177.78% | 2 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $99 | $62.40 | +58.65% | 3 | May 5, 2022 |
RxSight
Feb 26, 2026
Maintains: Neutral
Price Target: $11 → $10
Current: $6.26
Upside: +59.74%
Tactile Systems Technology
Feb 18, 2026
Maintains: Overweight
Price Target: $35 → $42
Current: $26.86
Upside: +56.37%
Inspire Medical Systems
Feb 12, 2026
Maintains: Overweight
Price Target: $165 → $85
Current: $52.07
Upside: +63.24%
Edwards Lifesciences
Feb 11, 2026
Reiterates: Overweight
Price Target: $98 → $100
Current: $81.69
Upside: +22.41%
ResMed
Jan 30, 2026
Maintains: Neutral
Price Target: $270 → $275
Current: $228.19
Upside: +20.51%
Intuitive Surgical
Jan 23, 2026
Maintains: Overweight
Price Target: $610 → $620
Current: $471.91
Upside: +31.38%
Abbott Laboratories
Jan 23, 2026
Maintains: Overweight
Price Target: $150 → $135
Current: $104.06
Upside: +29.73%
Sight Sciences
Jan 5, 2026
Upgrades: Overweight
Price Target: $5 → $9
Current: $3.85
Upside: +133.77%
Nyxoah
Nov 14, 2025
Reiterates: Overweight
Price Target: $12 → $9
Current: $3.19
Upside: +182.57%
InspireMD
May 12, 2025
Maintains: Overweight
Price Target: $4.5 → $4
Current: $1.79
Upside: +123.46%
May 22, 2024
Maintains: Hold
Price Target: $20 → $21
Current: $18.38
Upside: +14.25%
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $1.46
Upside: +449.83%
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $1.80
Upside: +177.78%
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $62.40
Upside: +58.65%